XML 92 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue by product
Revenue by product are summarized as follows:
 For the Years Ended December 31,
 202420232022
(In millions)United
States		Rest of
World		TotalUnited
States		Rest of
World		TotalUnited
States		Rest of
World		Total
Multiple Sclerosis:
TECFIDERA$169.2 $797.9 $967.1 $263.1 $749.4 $1,012.5 $417.7 $1,026.2 $1,443.9 
VUMERITY538.6 89.4 628.0 512.1 64.2 576.3 521.3 32.1 553.4 
Total Fumarate707.8 887.3 1,595.1 775.2 813.6 1,588.8 939.0 1,058.3 1,997.3 
AVONEX451.3 256.2 707.5 536.7 274.3 811.0 649.2 324.3 973.5 
PLEGRIDY111.4 149.1 260.5 126.2 168.5 294.7 148.4 183.5 331.9 
Total Interferon562.7 405.3 968.0 662.9 442.8 1,105.7 797.6 507.8 1,305.4 
TYSABRI920.0 795.0 1,715.0 997.9 879.0 1,876.9 1,123.4 907.5 2,030.9 
FAMPYRA— 71.7 71.7 — 90.5 90.5 — 96.6 96.6 
Subtotal: Multiple Sclerosis2,190.5 2,159.3 4,349.8 2,436.0 2,225.9 4,661.9 2,860.0 2,570.2 5,430.2 
Rare Disease:
SPINRAZA625.7 947.5 1,573.2 610.5 1,130.7 1,741.2 600.2 1,193.3 1,793.5 
SKYCLARYS(1)
301.1 81.4 382.5 55.9 — 55.9 — — — 
QALSODY(2)
20.9 11.5 32.4 5.8 0.1 5.9 — — — 
Subtotal: Rare Disease947.7 1,040.4 1,988.1 672.2 1,130.8 1,803.0 600.2 1,193.3 1,793.5 
Biosimilars:
BENEPALI— 479.1 479.1 — 438.8 438.8 — 441.0 441.0 
IMRALDI— 213.1 213.1 — 222.1 222.1 — 224.5 224.5 
FLIXABI— 63.2 63.2 — 77.4 77.4 — 81.3 81.3 
BYOOVIZ(3)
23.0 13.6 36.6 29.2 2.5 31.7 4.3 — 4.3 
TOFIDENCE(4)
1.1 — 1.1 — — — — — — 
Subtotal: Biosimilars24.1 769.0 793.1 29.2 740.8 770.0 4.3 746.8 751.1 
Other:
ZURZUVAE(5)
72.2 — 72.2 1.6 — 1.6 — — — 
Other(6)
2.8 7.5 10.3 2.4 7.8 10.2 4.8 8.2 13.0 
Subtotal: Other75.0 7.5 82.5 4.0 7.8 11.8 4.8 8.2 13.0 
Total product revenue, net$3,237.3 $3,976.2 $7,213.5 $3,141.4 $4,105.3 $7,246.7 $3,469.3 $4,518.5 $7,987.8 
(1) SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.
(2) QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.
(3) BYOOVIZ became commercially available in certain international markets in 2023.
(4) TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.
(5) ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.
(6) Other includes FUMADERM and ADUHELM.
Analysis of change in reserves
An analysis of the change in reserves for discounts and allowances is summarized as follows:
December 31, 2024
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2023$173.3 $857.1 $31.6 $1,062.0 
Current provisions relating to sales in current year824.2 2,687.5 23.6 3,535.3 
Adjustments relating to prior years8.0 (38.7)14.2 (16.5)
Payments/credits relating to sales in current year(670.9)(1,989.7)(0.6)(2,661.2)
Payments/credits relating to sales in prior years(171.9)(635.4)(20.7)(828.0)
Balance, December 31, 2024$162.7 $880.8 $48.1 $1,091.6 
December 31, 2023
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2022$153.8 $857.7 $23.5 $1,035.0 
Current provisions relating to sales in current year735.6 2,720.1 19.0 3,474.7 
Adjustments relating to prior years(0.4)(38.4)19.2 (19.6)
Payments/credits relating to sales in current year(572.9)(1,944.8)(2.1)(2,519.8)
Payments/credits relating to sales in prior years(142.8)(737.5)(28.0)(908.3)
Balance, December 31, 2023$173.3 $857.1 $31.6 $1,062.0 
December 31, 2022
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2021$137.7 $759.6 $38.0 $935.3 
Current provisions relating to sales in current year666.6 2,715.5 12.3 3,394.4 
Adjustments relating to prior years(2.8)1.4 (7.2)(8.6)
Payments/credits relating to sales in current year(514.9)(2,060.7)(1.2)(2,576.8)
Payments/credits relating to sales in prior years(132.8)(558.1)(18.4)(709.3)
Balance, December 31, 2022$153.8 $857.7 $23.5 $1,035.0 
Total reserves included in consolidated balance sheet
The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
 As of December 31,
(In millions)20242023
Reduction of accounts receivable$154.1 $135.5 
Component of accrued expense and other937.5 926.5 
Total revenue-related reserves$1,091.6 $1,062.0 
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Years Ended December 31,
(In millions)202420232022
Royalty revenue on sales of OCREVUS$1,339.5 $1,266.2 $1,136.3 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO(1)
392.0 409.4 547.0 
Other revenue from anti-CD20 therapeutic programs18.4 14.0 17.2 
Total revenue from anti-CD20 therapeutic programs$1,749.9 $1,689.6 $1,700.5 
(1) LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.
Revenue from anti-CD20 therapeutic programs is summarized as follows:
 For the Years Ended December 31,
(In millions)202420232022
Royalty revenue on sales of OCREVUS$1,339.5 $1,266.2 $1,136.3 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO(1)
392.0 409.4 547.0 
Other revenue from anti-CD20 therapeutic programs18.4 14.0 17.2 
Total revenue from anti-CD20 therapeutic programs$1,749.9 $1,689.6 $1,700.5 
(1) LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.
Other revenues
Contract manufacturing, royalty and other revenue is summarized as follows:
 For the Years Ended December 31,
(In millions)202420232022
Contract manufacturing revenue$592.1 $848.2 $417.7 
Royalty and other revenue60.5 51.1 67.4 
Total contract manufacturing, royalty and other revenue$652.6 $899.3 $485.1